Incidence and risk factors for early thyroxin supplementation therapy after hemithyroidectomy for benign conditions in Europe. A Eurocrine® registry-based study.

Overall, 32.1% of patients who underwent hemithyroidectomy for benign conditions received early postoperative replacement therapy (EPRT).

• 4,653 out of 14,484 patients received EPRT assessed 30–45 days after surgery.
• The study included patients undergoing HT between 2015 and 2022 from the Eurocrine® database.
• Median age was 52 years and 11,345 (78.3%) were female.
• The most common indication for surgery was excluding malignancy in 7,873 cases (54.3%).

There was significant variability in EPRT prescription rates among European countries, ranging from 3% to 95%.

• The country where HT was performed was identified as an independent predictor of EPRT in multivariate logistic regression.
• National or local policies were noted as potential influences on early prescription patterns.
• The study was multicenter and retrospective, drawing from the Eurocrine® registry across multiple European countries.

Female sex was identified as an independent risk factor for receiving EPRT after hemithyroidectomy.

• Female sex was included as a significant predictor in the multivariate logistic regression model.
• 78.3% of the study population (11,345 out of 14,484) were female.
• Associations between qualitative variables and likelihood of EPRT were tested using Chi-square or Fisher's exact tests before multivariate analysis.

Older age was an independent risk factor for receiving EPRT after hemithyroidectomy.

• Older age was identified as an independent predictor in the multivariate logistic regression model.
• The overall median age of the study population was 52 years.
• The study analyzed epidemiological, clinical, surgical, and pathological variables as potential predictors.

Malignancy and thyrotoxicosis as surgical indications were independent risk factors for EPRT prescription.

• Both malignancy (excluding malignancy) and thyrotoxicosis as surgical indications were identified as independent predictors in multivariate logistic regression.
• Excluding malignancy was the most common surgical indication, present in 7,873 cases (54.3%).
• Despite the study focusing on histologically proven benign conditions, the preoperative indication of suspected malignancy still influenced EPRT prescription.

Bethesda III cytology classification was an independent risk factor for EPRT after hemithyroidectomy.

• Bethesda III (atypia of undetermined significance/follicular lesion of undetermined significance) cytology was identified as an independent predictor in the multivariate logistic regression model.
• Cytological data was among the analyzed clinical and pathological variables.
• The dependent variable EPRT was assessed 30–45 days after surgery.

Thyroiditis found on histological examination was an independent risk factor for EPRT prescription.

• Thyroiditis on histology was identified as a significant independent predictor in the multivariate logistic regression model.
• Pathological data including histological findings were among the analyzed variables.
• All included patients had histologically proven benign conditions, yet thyroiditis subtype conferred additional risk.

The study population comprised 14,484 patients undergoing hemithyroidectomy for histologically proven benign conditions across Europe between 2015 and 2022.

• Data were drawn from the Eurocrine® registry in a retrospective, multicenter design.
• Median age was 52 years and 78.3% were female.
• The dependent variable was EPRT, assessed at the first postoperative visit 30–45 days after surgery.
• Analyzed variables included country of surgery, epidemiological, clinical, surgical, and pathological data.